Publications by authors named "Xingsheng Yao"
Background: Synthetic thymic peptides (sTPs) are used with chemotherapy to treat non-small cell lung cancer (NSCLC). In this study, we have performed a systematic review and meta-analysis of published trials to confirm the clinical efficacy and safety of sTPs, and determine the optimal types, usages, and sTP/chemotherapy combinations to produce the desired responses.
Materials And Methods: We collected all studies regarding combined sTP therapy and chemotherapy for NSCLC from the Chinese and English databases (up to October 2018).
Article Synopsis
- Aidi injection is used as an adjuvant chemotherapy in China, specifically for non-small-cell lung cancer (NSCLC), but evidence supporting its effectiveness alongside platinum-based chemotherapy is limited.
- A systematic review of 17 randomized controlled trials with 1,390 NSCLC patients found that combining Aidi injection with platinum chemotherapy improved objective response rate (ORR) and disease control rate (DCR), indicating enhanced clinical efficacy.
- Despite statistically significant improvements in cellular immunity markers (like CD3T and CD4T cells), the findings may not be entirely reliable and could be overestimated or underestimated.
Antibiotic production in Streptomyces lividans can be activated by introducing certain mutations (rif) into the rpoB gene that confer resistance to rifampicin. Working with the most typical (rif-17) mutant strain, KO-417, the rif-17 mutation was characterized. The rif-17 mutation was shown to be responsible for activating antibiotic production and for reducing the growth rate of strain KO-417, as demonstrated by gene-replacement experiments.
View Article and Find Full Text PDF